[Approval of HIV protease inhibitors as the AIDS therapeutics of next generation].
The long-term usages of reverse transcriptase inhibitors as anti-HIV drugs have induced serious side effects and emergence of resistant viruses. To overcome these problems, combination therapies are expected to be effective. Under such circumstances, HIV protease inhibitors have been rationally designed and synthesized based on the substrate transition state concept. HIV protease inhibitors act at the exact point in the life cycle of HIV, exhibited efficacy in the clinical trials and have been approved with high expectation. The introduction of anti-HIV drug with novel action mechanism evoked a new dramatic movement in the combination therapy of AIDS.
Kiso
Y
Y
Kyoto Pharmaceutical University.
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents; D002986:Clinical Trials as Topic; D015195:Drug Design; D016333:HIV Protease / Q000737:chemistry / Q000235:genetics; D017320:HIV Protease Inhibitors; D015497:HIV-1 / Q000235:genetics; D015498:HIV-2 / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D016333:HIV Protease